The LDN Research Trust, which was founded in the United Kingdom, is hosting its 2020 Low Dose Naltrexone (LDN) Conference at The Grand Hyatt Baha Mar, One Baha Mar Boulevard Hotel om 12th February 2020. The conference will feature 7 expert medical speakers, including a Rheumatologist and Oncologist.
The Trust was asked to bring this conference to the Bahamas to help and support those people living with Autoimmune Diseases, Cancers and Chronic pain and to educate with medical professionals about this nontoxic, inexpensive drug that is used in very low doses, which has little to no side effects. This conference will achieve just that!
The conference will bring together medical researchers, physicians, and pharmacists to promote the latest research, trials, and studies in the hope of making low dose naltrexone a first-line treatment. One of the goals is to educate how to customize the correct dosing for patients, and educate pharmacists so they, in turn, can help and educate their own prescribers.
“Each one of our conferences is unique, and the 2020 Conference looks in-depth at ultra-low dose, starting at just two micrograms, which is used to wean people off opioids without causing withdrawal symptoms,” says Linda Elsegood, CEO of LDN Research Trust. “The last four conferences had 230 topics presented by experienced prescribers who showed new and novel ways to help patients. Each conference builds on the last giving the latest updated information.”
In addition to raising funding for clinical trials, the LDN Research Trust has helped more than 90,000 people obtain low dose naltrexone from a general practitioner or consultant, either through the National Health Service or by private prescription. The organization has helped people in the United Kingdom, throughout Europe, and United States, Canada, West Indies, Australia, New Zealand, and beyond.
For more information about the organization and registration for the 2020 Low Dose Naltrexone Conference, visit www.ldnrtevents.com/pages/ldn-2020-bahamas
About LDN Research Trust
In 2004, the LDN Research Trust was founded in the United Kingdom. The primary aim of the organization, which helps people around the world, is to initiate clinical trials of low dose naltrexone for autoimmune diseases and cancers. To learn more visit, LDNResearchTrust.org.
